Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

IRulya Therapeutics Inc.

NASDAQ: IRLA · Life Sciences · 6 alerts · CIK 1662774

Share price
$37.36Close, Nov 16
Market cap
$405M
Shares outstanding
10.84MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All IRulya Therapeutics Inc. filings on SEC EDGAR ↗

7:59 AM ET 8-K
Leadership Change

Quince Therapeutics Leadership Change

Quince Therapeutics (renaming to IRulya Therapeutics) announced the resignation of CEO Dirk Thye and COO Brendan Hannah, effective October 8, 2026. Brigette Roberts, M.D., has been appointed as the new Chief Executive Officer, bringing a base salary of $600,000 and a 50% target bonus. The leadership transition coincides with a corporate rebrand and a strategic focus on the clinical development of LAM-001 for pulmonary diseases.

7:30 AM ET 8-K
Leadership Change

Quince Therapeutics Leadership Change

Quince Therapeutics announced the conditional resignations of three board directors (June Bray, David Lamond, and Christopher Senner) and the appointment of four new directors (Catherine Bonuccelli, Leone Patterson, James Valentine, and Drayton Wise). These changes are contingent upon shareholder approval of several proposals at a Special Meeting on October 6, 2026, including a conversion proposal that may result in a change of control. The resignations were not due to any disagreements with the company's operations or policies.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.